Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type XXII alpha 1 chain (COL22A1) is a minor collagen protein integrated into the extracellular matrix, notable for its localization at tissue junctions in muscle, tendons, heart, articular cartilage, and skin. It plays a key role in stabilizing myotendinous junctions, supporting skeletal muscle contraction, and contributing to vascular integrity. COL22A1 is concentrated in the basement membrane zone and acts as a ligand for cell adhesion processes. Genetic disruption or mutation, notably the E736D substitution, has been implicated in increased vascular fragility, leading to conditions such as intracranial aneurysms and hemorrhage in animal models. COL22A1 also mediates fibroblast-to-myofibroblast transition in fibrotic disease states (e.g., systemic sclerosis). There are currently no known drugs that target this protein, nor is it considered a canonical drug target such as a receptor or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type XXII alpha 1 chain (COL22A1).